NCT04521686 2025-06-27
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
Eli Lilly and Company
Xennials Therapeutics Australia Pty Ltd
Case Comprehensive Cancer Center
Hospital Sant Joan de Deu
Barbara Ann Karmanos Cancer Institute
Peking Union Medical College Hospital
Gustave Roussy, Cancer Campus, Grand Paris